{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009641","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.383595+00:00","generated_at":"2026-05-27T02:51:49.498976+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M","bullets":["Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.","Reaffirms FY2024 guidance: net product revenue $55-60M, SG&A $39-42M, R&D $8-10M.","Hosts Feb 5, 2025 conference call to update commercial launch plan for Emrosi (minocycline HCl ER 40 mg).","Investor presentation (Exhibit 99.1) attached but specific slide content not disclosed in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009641","json":"https://secwatch.observer/filing/0001104659-25-009641.json","markdown":"https://secwatch.observer/filing/0001104659-25-009641.md","text":"https://secwatch.observer/filing/0001104659-25-009641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/0001104659-25-009641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/tm255603d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:51:49.498976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}